Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL

Journal of the Neurological Sciences

Volumn 260, Issue 1-2, 2007, Pages 100-105

  Peters, Nils ^a   Freilinger, Tobias ^a   Opherk, Christian ^a   Pfefferkorn, Thomas ^a   Dichgans, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CADASIL; l Arginine; NO; Statin; Transcranial Doppler sonography; Treatment; Vasoreactivity

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ATORVASTATIN; CARBON DIOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; CADASIL; CLINICAL ARTICLE; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; FEMALE; HEMODYNAMICS; HUMAN; HYPERCAPNIA; MALE; MIDDLE CEREBRAL ARTERY; PRIORITY JOURNAL; VASOMOTOR REFLEX;

EID: 34547655456     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.04.015     Document Type: Article

References (40)

1. Endres M., Laufs U., Liao J.K., and Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci 27 (2004) 283-289
2. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
3. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 (1996) 1079-1082
4. Mason R.P., Walter M.F., and Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109 21 Suppl 1 (2004) II34-II41
5. Miida T., Hirayama S., and Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 11 (2004) 253-264
6. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
7. Egashira K., Inou T., Hirooka Y., Yamada A., Maruoka Y., Kai H., et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 91 (1993) 29-37
8. Bates K., Ruggeroli C.E., Goldman S., and Gaballa M.A. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 283 (2002) H768-H775
9. White H.D., Simes R.J., Anderson N.E., Hankey G.J., Watson J.D., Hunt D., et al. Pravastatin therapy and the risk of stroke. N Engl J Med 343 (2000) 317-326
10. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95 (1998) 8880-8885
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
12. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
13. Terborg C., Gora F., Weiller C., and Rother J. Reduced vasomotor reactivity in cerebral microangiopathy : a study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke 31 (2000) 924-929
14. Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383 (1996) 707-710
15. Dichgans M., Mayer M., Uttner I., Bruning R., Muller-Hocker J., Rungger G., et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44 (1998) 731-739
16. Sterzer P., Meintzschel F., Rosler A., Lanfermann H., Steinmetz H., and Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 32 (2001) 2817-2820
17. Yamada M., Huang Z., Dalkara T., Endres M., Laufs U., Waeber C., et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by l-arginine after chronic statin treatment. J Cereb Blood Flow Metab 20 (2000) 709-717
18. Dalkara T., Morikawa E., Panahian N., and Moskowitz M.A. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am J Physiol 267 (1994) H678-H683
19. Pretnar-Oblak J., Sabovic M., Sebestjen M., Pogacnik T., and Zaletel M. Influence of atorvastatin treatment on l-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 37 (2006) 2540-2545
20. Ruchoux M.M., and Maurage C.A. CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 56 (1997) 947-964
21. Ruchoux M.M., Chabriat H., Bousser M.G., Baudrimont M., and Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 25 (1994) 2291-2292
22. Peters N., Opherk C., Bergmann T., Castro M., Herzog J., and Dichgans M. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol 62 (2005) 1091-1094
23. Joutel A., Vahedi K., Corpechot C., Troesch A., Chabriat H., Vayssiere C., et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350 (1997) 1511-1515
24. Mayer M., Straube A., Bruening R., Uttner I., Pongratz D., Gasser T., et al. Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL. J Neurol 246 (1999) 526-532
25. O'Sullivan M., Jarosz J.M., Martin R.J., Deasy N., Powell J.F., and Markus H.S. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 56 (2001) 628-634
26. Auer D.P., Putz B., Gossl C., Elbel G., Gasser T., and Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology 218 (2001) 443-451
27. Chabriat H., Levy C., Taillia H., Iba-Zizen M.T., Vahedi K., Joutel A., et al. Patterns of MRI lesions in CADASIL. Neurology 51 (1998) 452-457
28. Holtmannspotter M., Peters N., Opherk C., Martin D., Herzog J., Bruckmann H., et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke 36 (2005) 2559-2565
29. Pfefferkorn T., von Stuckrad-Barre S., Herzog J., Gasser T., Hamann G.F., and Dichgans M. Reduced cerebrovascular CO(2) reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 32 (2001) 17-21
30. Zimmermann C., Wimmer M., and Haberl R.L. l-arginine-mediated vasoreactivity in patients with a risk of stroke. Cerebrovasc Dis 17 (2004) 128-133
31. Singhal S., and Markus H.S. Cerebrovascular reactivity and dynamic autoregulation in nondemented patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). J Neurol 252 (2005) 163-167
32. Ruchoux M.M., and Maurage C.A. Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol Appl Neurobiol 24 (1998) 60-65
33. Waters D.D., Schwartz G.G., Olsson A.G., Zeiher A., Oliver M.F., Ganz P., et al. MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695
34. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
35. Ernst E., and Resch K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118 (1993) 956-963
36. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
37. van Oijen M., Witteman J.C., Hofman A., Koudstaal P.J., and Breteler M.M. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36 (2005) 2637-2641
38. Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2003; 2004; 33:256-61.
39. Morange P.E., Simon C., Alessi M.C., Luc G., Arveiler D., Ferrieres J., et al. PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109 (2004) 1343-1348
40. Borawski J., Naumnik B., and Mysliwiec M. Circulating endothelial markers and probability of stroke in haemodialysis patients. Blood Coagul Fibrinolysis 14 (2003) 315-317